Severe Interstitial Lung Disease With First‐Line Enfortumab Vedotin Plus Pembrolizumab in Japanese Real‐World Practice

Ryo Kasahara

doi:10.1111/iju.70660

Enriched record

Severe Interstitial Lung Disease With First‐Line Enfortumab Vedotin Plus Pembrolizumab in Japanese Real‐World Practice

Ryo Kasahara

International Journal of Urology2026doi:10.1111/iju.70660

Citation graph

Abstract

No public abstract is available from the verified source records.

Authors

Ryo Kasahara#1

Institutions

No ROR-resolved institution is linked to this work yet.

Provenance

crossref

Confidence 100%

pubmed

Confidence 98%

datacite

Confidence 0%

Referenced works

View all references →

No local reference links have been materialized yet.

Cited by

View all cited-by records →

No local citing links have been materialized yet.

External reference records

10.1056/nejmoa2312117

10.3390/cancers18050739

Increased Risk of Interstitial Lung Disease With Enfortumab Vedotin Plus Pembrolizumab Compared With Sequential Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study in Japan

2026

10.1093/jjco/hyaf182

Unresolved referenced work

2024

Additional external references

No additional external references are available.